LRRK2 in Parkinson's disease: biochemical functions
- PMID: 19804416
- DOI: 10.1111/j.1742-4658.2009.07341.x
LRRK2 in Parkinson's disease: biochemical functions
Abstract
Leucine-rich repeat kinase 2 (LRRK2) is a large, complex, multidomain protein containing kinase and GTPase enzymatic activities and multiple protein-protein interaction domains. Mutations linked to autosomal dominant forms of Parkinson's disease result in amino acid changes throughout the protein and alterations in both its enzymatic properties and interactions. The best characterized mutation to date, G2019S, leads to increased kinase activity, and mutations in the GTPase domain, such as R1441C and R1441G, have also been reported to influence kinase activity. Therefore, an examination of LRRK2's properties as a kinase is important for understanding the mechanisms underlying the disorder and has the potential to lead to therapeutics. These findings also suggest that there may be complex interplay between the functional domains of LRRK2. Here, we review LRRK2's biochemical functions based on structural and kinetic studies of the enzymatic domains, its potential substrates and the role of its interactions. Despite the field's embryonic understanding of the true relevance of these substrates and interactions, initial studies are providing clues with respect to its pathophysiological functions. Together, these findings should increase our understanding of mechanisms underlying Parkinson's disease and place LRRK2 as a unique molecular target for effective therapeutic development.
Similar articles
-
Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.BMB Rep. 2010 Apr;43(4):233-44. doi: 10.5483/bmbrep.2010.43.4.233. BMB Rep. 2010. PMID: 20423607 Review.
-
LRRK2 in Parkinson's disease: protein domains and functional insights.Trends Neurosci. 2006 May;29(5):286-93. doi: 10.1016/j.tins.2006.03.006. Epub 2006 Apr 17. Trends Neurosci. 2006. PMID: 16616379 Review.
-
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.J Neurochem. 2007 Oct;103(1):238-47. doi: 10.1111/j.1471-4159.2007.04743.x. Epub 2007 Jul 10. J Neurochem. 2007. PMID: 17623048 Free PMC article.
-
LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.Biochem Soc Trans. 2012 Oct;40(5):1074-9. doi: 10.1042/BST20120093. Biochem Soc Trans. 2012. PMID: 22988868 Free PMC article. Review.
-
Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.J Neurosci Res. 2009 May 1;87(6):1283-95. doi: 10.1002/jnr.21949. J Neurosci Res. 2009. PMID: 19025767 Free PMC article. Review.
Cited by
-
Inflammation and immune dysfunction in Parkinson disease.Nat Rev Immunol. 2022 Nov;22(11):657-673. doi: 10.1038/s41577-022-00684-6. Epub 2022 Mar 4. Nat Rev Immunol. 2022. PMID: 35246670 Free PMC article. Review.
-
Lrrk2 localization in the primate basal ganglia and thalamus: a light and electron microscopic analysis in monkeys.Exp Neurol. 2010 Aug;224(2):438-47. doi: 10.1016/j.expneurol.2010.05.004. Epub 2010 May 17. Exp Neurol. 2010. PMID: 20483355 Free PMC article.
-
LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function.Hum Mol Genet. 2019 Aug 15;28(16):2696-2710. doi: 10.1093/hmg/ddz088. Hum Mol Genet. 2019. PMID: 31039583 Free PMC article.
-
Targeting GTPases in Parkinson's disease: comparison to the historic path of kinase drug discovery and perspectives.Front Mol Neurosci. 2014 Jun 5;7:52. doi: 10.3389/fnmol.2014.00052. eCollection 2014. Front Mol Neurosci. 2014. PMID: 24926233 Free PMC article. Review.
-
Mitochondria: Powering the Innate Immune Response to Mycobacterium tuberculosis Infection.Infect Immun. 2021 Mar 17;89(4):e00687-20. doi: 10.1128/IAI.00687-20. Print 2021 Mar 17. Infect Immun. 2021. PMID: 33558322 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical